American Cancer Society leans on pharma partners for equity, patient care and screening collaborations
The American Cancer Society is both a young and an old organization, CEO Karen Knudsen said in a recent interview with Endpoints News. Although founded more than 100 years ago, it operated as a federated model with regional separate non-profit groups until less than a decade ago. That meant each regional group crafted its own strategies and cancer action plans across the different geographies.
Today, however, it works with pharma in ways it couldn’t when it was operating under the federated system, she said. In the past five months, the American Cancer Society (ACS) has announced collaborations with Roche’s Genentech, AstraZeneca and Johnson & Johnson’s Janssen. While the donations are all single-digit million-dollar deals — and far from a large source of ACS funding — the work is emblematic of the newer style of pharma-funding relationships.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.